Trade Names:Ludiomil- Tablets 25 mg- Tablets 50 mg- Tablets 75 mgNovo-Maprotiline (Canada)
Inhibits norepinephrine (but not serotonin) reuptake.
Mean T max is 12 h.
Maprotiline protein binding is 88% and apparent Vd is 13 to 24 L/kg.
Maprotiline is metabolized in the liver.
Maprotiline is excreted in urine and feces. The mean t ½ is 51 h.
Depression; anxiety associated with depression.
Relief of chronic neurogenic pain.
Hypersensitivity to tricyclic antidepressants; MI acute recovery period; seizure disorder; concomitant use with MAOIs.
PO 25 to 75 mg/day as single dose or divided doses. May be increased to 150 mg/day (outpatient) or 225 mg/day (inpatient).
Store at controlled room temperature.
Additive CNS effects possible.MAOIs
May precipitate hypertensive crisis and convulsions with possibly fatal results. Discontinue at least 14 days before starting maprotiline.
None well documented.
Syncope; tachycardia; palpitations; orthostatic hypotension; hypertension; MI; arrhythmias; heart block.
Drowsiness; dizziness; hallucinations; disorientation; mania; exacerbation of psychosis; nervousness; fatigue; headache; anxiety; tremor; insomnia; agitation; seizures.
Blurred vision; mydriasis.
Dry mouth; constipation; nausea; diarrhea.
Impotence; urinary retention.
Bone marrow depression, including agranulocytosis; eosinophilia; purpura; thrombocytopenia; leukopenia.
Increased bilirubin and alkaline phosphatase.
Altered blood glucose levels.
Hypersensitivity (eg, rash, itching, photosensitivity, petechiae, edema, drug fever).
Category B .
Excreted in breast milk.
Safety and efficacy not established.
Use lower doses.
Use with caution in patients with history of seizures, urinary retention, urethral or ureteral spasm, angle-closure glaucoma or increased IOP, CV disorders, hyperthyroid patients or those receiving thyroid medication, hepatic or renal function impairment, schizophrenic or paranoid patients.
Do not allow patient to possess more than small quantities of drug.
May occur in therapeutic dose or overdose.
Hypotension, tachycardia, ventricular arrhythmias, CNS depression, seizures, respiratory depression, coma.
Copyright © 2009 Wolters Kluwer Health.